• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology.

作者信息

Ackerman Michael J, Zipes Douglas P, Kovacs Richard J, Maron Barry J

出版信息

Circulation. 2015 Dec 1;132(22):e326-9. doi: 10.1161/CIR.0000000000000246. Epub 2015 Nov 2.

DOI:10.1161/CIR.0000000000000246
PMID:26527716
Abstract
摘要

相似文献

1
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology.心血管异常竞技运动员的资格认定与取消资格建议：特别工作组10：心脏离子通道病：美国心脏协会和美国心脏病学会的科学声明
Circulation. 2015 Dec 1;132(22):e326-9. doi: 10.1161/CIR.0000000000000246. Epub 2015 Nov 2.
2
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 10: The Cardiac Channelopathies: A Scientific Statement From the American Heart Association and American College of Cardiology.患有心血管异常的竞技运动员的资格与取消资格建议：特别工作组10：心脏离子通道病：美国心脏协会和美国心脏病学会的科学声明
J Am Coll Cardiol. 2015 Dec 1;66(21):2424-2428. doi: 10.1016/j.jacc.2015.09.042. Epub 2015 Nov 2.
3
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 5: Valvular Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.患有心血管异常的竞技运动员的资格认定与取消资格建议：第5工作组：心脏瓣膜病：美国心脏协会和美国心脏病学会的科学声明
Circulation. 2015 Dec 1;132(22):e292-7. doi: 10.1161/CIR.0000000000000241. Epub 2015 Nov 2.
4
Eligibility and Disqualification Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Task Force 8: Coronary Artery Disease: A Scientific Statement from the American Heart Association and American College of Cardiology.心血管异常竞技运动员的资格认定与取消资格建议：第8工作组：冠状动脉疾病：美国心脏协会和美国心脏病学会的科学声明
Circulation. 2015 Dec 1;132(22):e310-4. doi: 10.1161/CIR.0000000000000244. Epub 2015 Nov 2.
5
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 14: Sickle Cell Trait: A Scientific Statement From the American Heart Association and American College of Cardiology.心血管异常竞技运动员的资格与取消资格建议：特别工作组14：镰状细胞性状：美国心脏协会和美国心脏病学会的科学声明
Circulation. 2015 Dec 1;132(22):e343-5. doi: 10.1161/CIR.0000000000000250. Epub 2015 Nov 2.
6
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 6: Hypertension: A Scientific Statement from the American Heart Association and the American College of Cardiology.心血管异常竞技运动员的资格认定与取消资格建议：特别工作组6：高血压：美国心脏协会和美国心脏病学会的科学声明
Circulation. 2015 Dec 1;132(22):e298-302. doi: 10.1161/CIR.0000000000000242. Epub 2015 Nov 2.
7
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes: A Scientific Statement From the American Heart Association and American College of Cardiology.心血管异常竞技运动员的资格与取消资格建议：特别工作组2：竞技运动员心血管疾病的赛前筛查：美国心脏协会和美国心脏病学会的科学声明
Circulation. 2015 Dec 1;132(22):e267-72. doi: 10.1161/CIR.0000000000000238. Epub 2015 Nov 2.
8
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 11: Drugs and Performance-Enhancing Substances: A Scientific Statement From the American Heart Association and American College of Cardiology.患有心血管异常的竞技运动员的资格认定与取消资格建议：第11工作组：药物与提高成绩的物质：美国心脏协会和美国心脏病学会的科学声明
Circulation. 2015 Dec 1;132(22):e330-3. doi: 10.1161/CIR.0000000000000247. Epub 2015 Nov 2.
9
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 15: Legal Aspects of Medical Eligibility and Disqualification Recommendations: A Scientific Statement From the American Heart Association and American College of Cardiology.心血管异常竞技运动员的资格认定与取消资格建议：特别工作组15：医学资格认定与取消资格建议的法律层面：美国心脏协会和美国心脏病学会的科学声明
Circulation. 2015 Dec 1;132(22):e346-9. doi: 10.1161/CIR.0000000000000251. Epub 2015 Nov 2.
10
Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 13: Commotio Cordis: A Scientific Statement From the American Heart Association and American College of Cardiology.心血管异常竞技运动员的资格认定与取消资格建议：特别工作组13：心脏震荡伤：美国心脏协会和美国心脏病学会的科学声明
Circulation. 2015 Dec 1;132(22):e339-42. doi: 10.1161/CIR.0000000000000249. Epub 2015 Nov 2.

引用本文的文献

1
Cardiopulmonary Fitness and Physical Activity Among Children and Adolescents With Inherited Cardiac Disease.患有遗传性心脏病的儿童和青少年的心肺适能与身体活动
JAMA Netw Open. 2025 Feb 3;8(2):e2461795. doi: 10.1001/jamanetworkopen.2024.61795.
2
Drowning incidents precipitated by unusual causes (DIPUCs): A narrative review of their diagnoses, evaluation and management.特殊原因引发的溺水事件（DIPUCs）：对其诊断、评估及管理的叙述性综述
Resusc Plus. 2024 Sep 13;20:100770. doi: 10.1016/j.resplu.2024.100770. eCollection 2024 Dec.
3
Response from Harmon et al to Letter Regarding Article, "Sudden Cardiac Death in National Collegiate Athletic Association Athletes".
哈蒙等人对关于《美国大学体育协会运动员心源性猝死》一文的信件的回复。
Circulation. 2024 Sep 17;150(12):e257-e258. doi: 10.1161/CIRCULATIONAHA.124.070246. Epub 2024 Sep 16.
4
Electrophysiological Characteristics and Ablation Outcomes in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.儿茶酚胺敏感性多形性室性心动过速患者的电生理特征和消融结果。
J Am Heart Assoc. 2023 Dec 19;12(24):e031768. doi: 10.1161/JAHA.123.031768. Epub 2023 Dec 8.
5
Catecholaminergic Polymorphic Ventricular Tachycardia and Gene Therapy: A Comprehensive Review of the Literature.儿茶酚胺能多形性室性心动过速与基因治疗：文献综述
Cureus. 2023 Oct 30;15(10):e47974. doi: 10.7759/cureus.47974. eCollection 2023 Oct.
6
Rationale and Design of the ORCCA (Outcomes Registry for Cardiac Conditions in Athletes) Study.ORCCA（运动员心脏疾病结局注册研究）的研究背景和设计。
J Am Heart Assoc. 2023 Jun 6;12(11):e029052. doi: 10.1161/JAHA.122.029052. Epub 2023 Jun 1.
7
The safety of sports in children with inherited arrhythmia substrates.患有遗传性心律失常基质的儿童运动安全性。
Front Pediatr. 2023 Apr 4;11:1151286. doi: 10.3389/fped.2023.1151286. eCollection 2023.
8
Cardiorespiratory fitness, muscle fitness, and physical activity in children with long QT syndrome: A prospective controlled study.长QT综合征患儿的心肺适能、肌肉适能及身体活动：一项前瞻性对照研究。
Front Cardiovasc Med. 2023 Jan 11;9:1081106. doi: 10.3389/fcvm.2022.1081106. eCollection 2022.
9
Cardiopulmonary Resuscitation and Defibrillator Use in Sports.体育运动中的心肺复苏与除颤器使用
Front Cardiovasc Med. 2022 Feb 15;9:819609. doi: 10.3389/fcvm.2022.819609. eCollection 2022.
10
Successful Management of a Young Athlete with Type 2 Long QT Syndrome by Genotype-specific Risk Stratification and Bridging Therapy with a Wearable Cardioverter Defibrillator.通过基因型特异性风险分层和可穿戴式心脏复律除颤器的桥接治疗成功管理一名患有2型长QT综合征的年轻运动员
Intern Med. 2022 Apr 15;61(8):1179-1182. doi: 10.2169/internalmedicine.8093-21. Epub 2022 Feb 1.